Foreign Competition Drives India Pharma Move To Greater R&D Investment
This article was originally published in PharmAsia News
Foreign competition has led Indian drug makers to invest more in research and development, to the extent the domestic industry has transformed itself into a major global hub worthy of eighth place among the world's countries in terms of R&D spending.
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.